Novan, Inc. Common Stock
NOVN
NOVN was delisted on the 25th of July, 2023.
38 hedge funds and large institutions have $8.92M invested in Novan, Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 13 increasing their positions, 12 reducing their positions, and 10 closing their positions.
8% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 12
17% less funds holding
Funds holding: 46 → 38 (-8)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
86% less capital invested
Capital invested by funds: $64.2M → $8.92M (-$55.2M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| 1 |
BlackRock
New York
|
+$1.82M |
| 2 |
ARTA
A.R.T. Advisors
New York
|
+$582K |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$522K |
| 4 |
Millennium Management
New York
|
+$135K |
| 5 |
State Street
Boston,
Massachusetts
|
+$106K |
Top Sellers
NOVN Hedge Fund Activity: Q1 2017 in Review
38 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Novan, Inc. Common Stock (NOVN) for Q1 2017, worth a combined $8.92M — down 86% from $64.2M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of NOVN and 8 opened new positions — a net loss of 2 holders — while 12 trimmed existing stakes and 13 added.
The largest buyer was BlackRock, adding an estimated $1.82M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $9.23M sold.
- 38 institutional investors held Novan, Inc. Common Stock (NOVN) as of Q1 2017, down from 46 in Q4 2016.
- Funds reported $8.92M of Novan, Inc. Common Stock stock for Q1 2017, down 86% quarter-over-quarter.
- 8 funds opened new Novan, Inc. Common Stock positions in Q1 2017 and 10 closed out, a net change of -2 holders.
- The largest Novan, Inc. Common Stock buyer in Q1 2017 was BlackRock, an estimated $1.82M added.
- The largest Novan, Inc. Common Stock seller in Q1 2017 was PFM Health Sciences, an estimated $9.23M sold.
Based on aggregated 13F filings for Q1 2017.